- Report
- March 2022
- 300 Pages
Global
From €4417EUR$5,000USD£3,852GBP
- Report
- July 2024
- 70 Pages
Global
From €4196EUR$4,750USD£3,659GBP
- Report
- December 2024
- 30 Pages
Global
From €2871EUR$3,250USD£2,504GBP
- Report
- August 2024
- 150 Pages
Global
From €3313EUR$3,750USD£2,889GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3313EUR$3,750USD£2,889GBP
- Report
- July 2024
- 150 Pages
Global
From €3313EUR$3,750USD£2,889GBP
- Report
- July 2024
- 100 Pages
Global
From €3313EUR$3,750USD£2,889GBP
- Report
- July 2024
- 150 Pages
Global
From €3313EUR$3,750USD£2,889GBP
- Report
- June 2024
- 200 Pages
Global
From €7024EUR$7,950USD£6,125GBP
- Report
- February 2024
- 30 Pages
Global
From €2871EUR$3,250USD£2,504GBP
- Report
- January 2024
- 189 Pages
Global
From €6626EUR$7,500USD£5,778GBP
- Report
- November 2023
- 30 Pages
Global
From €2430EUR$2,750USD£2,119GBP
- Report
- November 2023
- 30 Pages
Global
From €2430EUR$2,750USD£2,119GBP
- Report
- November 2023
- 30 Pages
Global
From €2430EUR$2,750USD£2,119GBP
- Report
- February 2023
- 107 Pages
Global
From €6626EUR$7,500USD£5,778GBP
- Report
- February 2023
- 50 Pages
Global
From €3490EUR$3,950USD£3,043GBP
From €3092EUR$3,500USD£2,696GBP
- Report
- February 2025
- 85 Pages
India
From €3092EUR$3,500USD£2,696GBP
- Report
- December 2024
- 85 Pages
India
From €3092EUR$3,500USD£2,696GBP
- Report
- April 2025
- 85 Pages
Saudi Arabia
From €3092EUR$3,500USD£2,696GBP

The insulin market is a subset of the larger endocrine and metabolic disorders drugs market. Insulin is a hormone produced by the pancreas that helps regulate the body's blood sugar levels. It is used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use it effectively. Insulin is available in both short-acting and long-acting forms, and is typically administered via injection or an insulin pump.
The insulin market is highly competitive, with a number of major pharmaceutical companies offering a variety of insulin products. These include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Additionally, there are a number of smaller companies that specialize in the production of insulin, such as Biocon, Wockhardt, and Wockhardt USA. Show Less Read more